-
1 Comment
Dr. Lal PathLabs Limited is currently in a long term uptrend where the price is trading 36.3% above its 200 day moving average.
From a valuation standpoint, the stock is 244.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16.5.
Dr. Lal PathLabs Limited's total revenue rose by 38.0% to $5B since the same quarter in the previous year.
Its net income has increased by 74.7% to $945M since the same quarter in the previous year.
Based on the above factors, Dr. Lal PathLabs Limited gets an overall score of 3/5.
CurrencyCode | INR |
---|---|
Exchange | NSE |
ISIN | INE600L01024 |
Industry | Diagnostics & Research |
Sector | Healthcare |
Market Cap | 158B |
---|---|
Beta | 0.33 |
Dividend Yield | 0.6% |
Target Price | 998 |
PE Ratio | 65.06 |
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LALPATHLAB.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024